4SC is a biopharmaceutical company developing small-molecule drugs that target key indications in cancer with unmet medical needs. Its current product pipeline includes two programs in clinical development: resminostat, an orally administered histone deacetylase (HDAC) inhibitor with a mechanism of action that represents a therapy for a spectrum of oncology indications, both in monotherapy and in combination with other anti-cancer drugs); and domatinostat, an orally administered histone deacetylase (HDAC) inhibitor with a mode of action that was designed to strengthen the body’s own anti-tumor immune response.